Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 16.39 Billion | USD 23.62 Billion | 3.7% | 2024 |
The global antifungal drug market size was worth around USD 16.39 Billion in 2024 and is predicted to grow to around USD 23.62 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 3.7% between 2025 and 2034. The report analyzes the global antifungal drug market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the antifungal drug industry.
Invasive fungal infections are a key cause of mortality in immune-compromised patients and this has proved to be an economic burden on the healthcare sector across the globe. As per NCBI, these infections have caused nearly 2 million fatalities each year. Moreover, recent antifungal drugs have proved to be less clinically efficient and new antifungal agents along with new combination regimens as well as new drug formulations for improving patient care will drive market trends. Furthermore, antifungal drugs eradicate pathogens from hosts with minimal side effects. In addition to this, the launching of novel antifungal medicines such as echinocandins and second-generation triazoles in the last few years has favorably influenced managing of invasive mycoses in a way that drug toxicity has become less vital factor in drug treatment of fungal infections.
Additionally, antifungal drugs are also referred to as antimycotic drugs and it is a fungistatic and utilized for treating mycosis including ringworm, athlete’s foot, cryptococcal meningitis, and candidiasis. Anti-fungal drugs can be bifurcated into three types, namely, azoles that inhibit ergosterol synthesis, polyenes that interact with fungal membrane sterols physio-chemically, and 5-flucytosine that obstruct macromolecular synthesis.
The occurrence of fungal infections in immune-compromised patients such as AIDS, cancer patients, and individuals affected due to autoimmune disorders will offer new growth avenues for the antifungal drug industry. The surge in the use of nanotechnology in the formulation of advanced antifungal medicines will impel the expansion of the antifungal drug industry. A prominent increase in nosocomial infections in patients will spearhead the demand for antifungal drugs in the healthcare sector. Nonetheless, the use of conventional medicines can hinder the growth of the antifungal drug industry.
Furthermore, an increase in awareness about fungal infections and a surge in drug demand for countering chronic fungal diseases will steer the penetration of antifungal drugs in the healthcare sector. This will spur an increase in the size of the antifungal drug market. Innovations in drug development and huge investments in drug research activities will prompt the expansion of the antifungal drug market.
The global antifungal drug market is segmented based on drug type, indication, dosage form, distribution channel, and region.
Based on drug type, the global market of antifungal drugs is bifurcated into five types: echinocandins, azoles, ployenes, allylamines and others. Azoles are systemically acting antifungal drug which include fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole. The echinocandins are lipopeptides derived from natural fungal fermentation products. They include anidulafungin, caspofungin and micafungin. Azole derivative was the leading derivative in terms of generating revenue in 2019 and this growth is expected to continue within the forecast period. The growth is attributed to the effective price and fungicidal properties of azole derivatives like ketoconazole, itraconazole, etc.
Based on indication, the global market of antifungal drugs is bifurcated into four types: aspergillosis, dermatophytosis, candidiasis and others. The most commonly encountered fungal infections are those that affect the skin layers. Approximately 1-2% of the world’s population is affected by dermatophytoses (superficial fungal infections of the skin). Seborrheic dermatitis, ringworm infection, and jock itch are examples of various topical fungal infections.
Based on dosage form, the global market of antifungal drugs is bifurcated into four types: powders, ointments, drugs and pastes. Over-the-counter antifungal drugs like clo-trimoxazole (sulphamethoxazole + trimethoprim) are available in powder, or ointment form and can be easily obtained without doctor/physician prescriptions. Whereas, the majority of oral antifungal drugs are prescription-based medicines and are available in various dosage forms such as tablets, capsules and suspensions. Powder, ointment covers approximately more than 55% of the antifungal drug market.
In terms of distribution channel, the global antifungal drug market is categorized into Hospital Pharmacies and Retail Pharmacies & Drug Stores.
Report Attributes | Report Details |
---|---|
Report Name | Antifungal Drug Market |
Market Size in 2024 | USD 16.39 Billion |
Market Forecast in 2034 | USD 23.62 Billion |
Growth Rate | CAGR of 3.7% |
Number of Pages | 190 |
Key Companies Covered | Aspergillus, Abbott Laboratories, Alternaria, Enzon Pharmaceuticals Inc., Pfizer Inc., Merck & Co., GlaxoSmithKline plc, Bayer Healthcare, Novartis AG, Sanofi S.A., Kramer Laboratories, and Gilead Sciences Inc, and others. |
Segments Covered | By Drug Type, By Indication, By Dosage Form, By Distribution Channel, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America To Account Substantially Towards Regional Market Share By 2028
The growth of the antifungal drug industry in North America over the forecast timespan is owing to a surge in the use of novel antifungal drugs for treating fungal infections. For instance, in December 2020, the U.S. FDA approved the application of Scynexis Inc. for its drug ibrexafungerp which has the ability for treating vaginal yeast infection. Apart from this, the rise in funding of research work related to new antifungal drugs will expand the scope of the antifungal drug market in years to come.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the antifungal drug market on a global and regional basis.
The global antifungal drug market is dominated by players like:
By Drug Type
By Indication
By Dosage Form
By Distribution Channel
By Region
FrequentlyAsked Questions
Leading players in the global antifungal drug market include Aspergillus, Abbott Laboratories, Alternaria, Enzon Pharmaceuticals Inc., Pfizer Inc., Merck & Co., GlaxoSmithKline plc, Bayer Healthcare, Novartis AG, Sanofi S.A., Kramer Laboratories, and Gilead Sciences Inc, among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed